Biomedical Engineering Reference
In-Depth Information
247. Weissleder, R.; Stark, D. D.; Engelstad, B. L.; Bacon, B. R.; Compton, C. C.; White, D. L.;
Jacobs, P.; Lewis, J. Superparamagnatic Iron Oxide: Pharmacokinetics and Toxicity.
Am. J.
Roentgenol.
1989,
152,
167-173.
248. Kim, Y. K.; Lee, J. M.; Kim, C. S.; Chung, G. H.; Kim, C. Y.; Kim, I. H. Detection of Liver
Metastases: Gadobenate Dimeglumine Enhanced Three Dimensional Dynamic Phases and
One Hour Delayed Phase MR Imaging Versus Superparamagnetic Iron Oxide Enhanced MR
Imaging.
Eur. Radiol.
2005,
15,
220-228.
249. Seneterre, E.; Taourel, P.; Bouvier, Y.; Pradel, J.; Van Beers, B.; Daures, J. P., et al. Detection
of Hepatic Metastases: Ferumoxides Enhanced MR Imaging Versus Unenhanced MR Imaging
and CT During Arterial Portography.
Radiology
1996,
200,
785-792.
250. Schnorr, J.; Wagner, S.; Abramjuk, C.; Drees, R.; Schink, T.; Schellenberger, E. A.,
et al. Focal Liver Lesions: SPIO, Gadolinium, and Ferucarbotran Enhanced Dynamic
T1 Weighted and Delayed T2 Weighted MR Imaging in Rabbits.
Radiology
2006,
240,
90-100.
251. Mori, K.; Fukuda, K.; Asaoka, H.; Ueda, T.; Kunimatsu, A.; Okamoto, Y., et al. Radiofre-
quency Ablation of the Liver: Determination of Ablative Margin at MR Imaging with Impaired
Clearance of Ferucarbotran-feasibility Study.
Radiology
2009,
251,
557-565.
252. Chen, R. C.; Lii, J. M.; Chou, C. T.; Chang, T. A.; Chen, W. T.; Li, C. S., et al. T2 Weighted
and T1 Weighted Dynamic Superparamagnetic Iron Oxide (ferucarbotran) Enhanced MRI
of Hepatocellular Carcinoma and Hyperplastic Nodules.
J. Formos Med. Assoc.
2008,
107,
798-805.
253. Kim, H. J.; Kim, K. W.; Byun, J. H.; Won, H. J.; Shin, Y. M.; Kim, P. N., et al. Comparison
of Mangafodipir Trisodium and Ferucarbotran Enhanced MRI for Detection and Character-
ization Of Hepatic Metastases in Colorectal Cancer Patients.
Am. J. Roentgenol.
2006,
186,
1059-1066.
254. Rogers, W. J.; Meyer, C. H.; Kramer, C. M. Technology Insight: In vivo Cell Tracking by Use
of MRI.
Nat. Clin. Pract. Cardiovasc. Med.
2006,
3,
554-562.
255. Islam, T.; Harisinghani, M. G. Overview of Nanoparticle Use in Cancer Imaging.
Cancer
Biomarkers
2009,
5,
61-67.
256. Heesakkers, R. A.; Jager, G. J.; Hovels, A. M.; de Hoop, B.; van den Bosch, H. C.; Raat, F.,
et al. Prostate Cancer: Detection of Lymph Node Metastases Outside the Routine Surgical
Area with Ferumoxtran10 Enhanced MR Imaging.
Radiology
2009,
251,
408-414.
257. Tang, T. Y.; Howarth, S. P.; Miller, S. R.; Graves, M. J.; Patterson, A. J.; UKingIm, J. M.,
et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activ-
ity) Study. Evaluation using ultrasmall superparamagnetic iron oxideenhanced magnetic reso-
nance imaging in carotid disease.
J. Am. Coll. Cardiol.
2009,
53,
2039-2050.
258. Reimer, P.; Bremer, C.; Allkemper, T.; Engelhardt, M.; Mahler, M.; Ebert, W., et al. Myocar-
dial perfusion and MR angiography of chest with SH U 555 C: results of placebo controlled
clinical phase i study.
Radiology
2004,
231,
474-481.
259. Wyttenbach, R.; Gianella, S.; Alerci, M.; Braghetti, A.; Cozzi, L.; Gallino, A. Prospective
Blinded Evaluation of GdDOTA Versus GdBOPTA Enhanced Peripheral MR Angiography,
As Compared with Digital Subtraction Angiography.
Radiology
2003,
227,
261-269.
260. Bremerich, J.; Bilecen, D.; Reimer, P. MR Angiography with Blood Pool Contrast Agents.
Eur.
Radiol.
2007,
17,
3017-3024.
261. Schnorr, J.; Wagner, S.; Abramjuk, C.; Wojner, I.; Schink, T.; Kroencke, T. J., et al. Compari-
son of the Iron Oxide Based Blood Pool Contrast Medium VSOPC184 with Gadopentetate
Dimeglumine for First Pass Magnetic Resonance Angiography of the Aorta and Renal Arteries
in Pigs.
Invest. Radiol.
2004,
39,
546-553.
